XML 46 R35.htm IDEA: XBRL DOCUMENT v3.5.0.2
SHAREHOLDERS' EQUITY (Tables)
 9 Months Ended
Sep. 30, 2016
Stockholders' Equity Note [Abstract]  
Schedule of shareholders' equity
 
Valeant Pharmaceuticals International, Inc. Shareholders
 
 
 
 
 
Common Shares
 
Additional
Paid-In
Capital
 
Accumulated
Deficit
 
Accumulated
Other
Comprehensive
Loss
 
Valeant
Pharmaceuticals
International, Inc.
Shareholders’
Equity
 
Noncontrolling
Interest
 
Total
Equity
 
Shares
(in millions)
 
Amount
 
 
 
 
 
 
Balance, January 1, 2015 (restated)
334.4

 
$
8,349.2

 
$
243.9

 
$
(2,397.8
)
 
$
(915.9
)
 
$
5,279.4

 
$
122.3

 
$
5,401.7

Issuance of common stock (see below)
7.5

 
1,481.0

 
—

 
—

 
—

 
1,481.0

 
—

 
1,481.0

Common shares issued under share-based compensation plans
1.4

 
75.7

 
(46.6
)
 
—

 
—

 
29.1

 
—

 
29.1

Repurchases of common shares
(0.2
)
 
(6.3
)
 
—

 
(43.7
)
 
—

 
(50.0
)
 
—

 
(50.0
)
Share-based compensation
—

 
—

 
111.4

 
—

 
—

 
111.4

 
—

 
111.4

Employee withholding taxes related to share-based awards
—

 
—

 
(85.8
)
 
—

 
—

 
(85.8
)
 
—

 
(85.8
)
Excess tax benefits from share-based compensation
—

 
—

 
21.7

 
—

 
—

 
21.7

 
—

 
21.7

Noncontrolling interest from business combinations
—

 
—

 
—

 
—

 
—

 
—

 
4.9

 
4.9

Noncontrolling interest distributions
—

 
—

 
—

 
—

 
—

 
—

 
(7.0
)
 
(7.0
)
 
343.1

 
9,899.6

 
244.6

 
(2,441.5
)
 
(915.9
)
 
6,786.8

 
120.2

 
6,907.0

Comprehensive loss:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income (restated)
—

 
—

 
—

 
94.2

 
—

 
94.2

 
4.4

 
98.6

Other comprehensive loss
—

 
—

 
—

 
—

 
(547.5
)
 
(547.5
)
 
(2.2
)
 
(549.7
)
Total comprehensive loss (restated)
 
 
 
 
 
 
 
 
 
 
(453.3
)
 
2.2

 
(451.1
)
Balance, September 30, 2015 (restated)
343.1

 
$
9,899.6

 
$
244.6

 
$
(2,347.3
)
 
$
(1,463.4
)
 
$
6,333.5

 
$
122.4

 
$
6,455.9

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance, January 1, 2016
342.9

 
$
9,897.4

 
$
304.9

 
$
(2,749.7
)
 
$
(1,541.6
)
 
$
5,911.0

 
$
118.8

 
$
6,029.8

Effect of retrospective application of a new accounting standard (see Note 3)
—

 
—

 
—

 
30.0

 
—

 
30.0

 
—

 
30.0

Common shares issued under share-based compensation plans
4.8

 
137.0

 
(103.9
)
 
—

 
—

 
33.1

 
—

 
33.1

Share-based compensation
—

 
—

 
134.0

 
—

 
—

 
134.0

 
—

 
134.0

Employee withholding taxes related to share-based awards
—

 
—

 
(9.1
)
 
—

 
—

 
(9.1
)
 
—

 
(9.1
)
Noncontrolling interest distributions
—

 
—

 
—

 
—

 
—

 
—

 
(9.1
)
 
(9.1
)
 
347.7

 
10,034.4

 
325.9

 
(2,719.7
)
 
(1,541.6
)
 
6,099.0

 
109.7

 
6,208.7

Comprehensive loss:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net loss(1)
—

 
—

 
—

 
(1,894.4
)
 
—

 
(1,894.4
)
 
(1.6
)
 
(1,896.0
)
Other comprehensive loss
—

 
—

 
—

 
—

 
(37.3
)
 
(37.3
)
 
(1.8
)
 
(39.1
)
Total comprehensive loss
 
 
 
 
 
 
 
 
 
 
(1,931.7
)
 
(3.4
)
 
(1,935.1
)
Balance, September 30, 2016(1)
347.7

 
$
10,034.4

 
$
325.9

 
$
(4,614.1
)
 
$
(1,578.9
)
 
$
4,167.3

 
$
106.3

 
$
4,273.6


____________________________________
(1)
As described in Note 3, the Company adopted the new accounting guidance on employee share-based payment transactions in the third quarter of 2016. As a result of the adoption, excess tax benefits and tax deficiencies are recognized in the provision for income taxes instead of additional paid-in capital. This aspect of the new guidance is adopted prospectively with the effective date of January 1, 2016. Given the adoption impact for the six months ended June 30, 2016 was insignificant, the Company recorded an adjustment for the cumulative adoption impact for the six months ended June 30, 2016 in the three months ended September 30, 2016. Refer to Note 3 for further details.